543635 and PPLPHARMA Related Headlines
Go Back- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
- Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
543635 and PPLPHARMA Related Press Releases
Go Back- Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
- Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
- Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
- Piramal Pharma Solutions Commemorates 20th Anniversary at Morpeth Facility with Procurement of Korsch X3 Tablet Press
- Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
- Piramal Pharma Limited Announces Results for Q3 and 9M FY26
- Piramal Pharma Solutions Demonstrates Commitment to Excellence with Outstanding Net Promoter Score
- Piramal Pharma Solutions Achieves Regulatory Compliance for Nitrosamine Impurities
- Piramal Pharma Limited Announces Results for Q2 and H1 FY26
- Piramal Pharma Solutions Augments Formulation Capabilities with the Addition of New Korsch XM-12 Bilayer Tablet Press at its Morpeth, UK Facility
- Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK™ (telmisartan, amlodipine and indapamide)
- Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
